Advertisement
Screener

LIFEVANTAGE CORP (LFVN) Dividends, Cash

2.8 / 5 stars · 68/120 Roast Me

LIFEVANTAGE CORP Dividends, Cash

LIFEVANTAGE CORP (LFVN) reported Dividends, Cash of $2.34 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.

Financial Statements › Shareholders' Equity

us-gaap:DividendsCash · last filed 2026-08-27

  • LIFEVANTAGE CORP dividends, cash for the quarter ending 2026-06-30 was $625.00K.
  • LIFEVANTAGE CORP dividends, cash for the quarter ending 2026-03-31 was $572.00K, a 13.72% increase year-over-year.
  • LIFEVANTAGE CORP dividends, cash for the quarter ending 2025-12-31 was $576.00K, a 14.74% increase year-over-year.
  • LIFEVANTAGE CORP dividends, cash for the quarter ending 2025-09-30 was $571.00K, a 14.20% increase year-over-year.
  • LIFEVANTAGE CORP dividends, cash for fiscal 2026 was $2.34M, a 13.40% increase from fiscal 2025.
  • LIFEVANTAGE CORP dividends, cash for fiscal 2025 was $2.07M, a 70.22% decline from fiscal 2024.
  • LIFEVANTAGE CORP dividends, cash for fiscal 2024 was $6.94M, a 337.58% increase from fiscal 2023.
  • LIFEVANTAGE CORP dividends, cash for fiscal 2023 was $1.59M, a 319.58% increase from fiscal 2022.
Period endDividends, Cash 3 monthDividends, Cash 6 monthDividends, Cash 9 monthDividends, Cash 12 month
2026-06-30$625.00K
derived: 10-K 12 month − 3 quarters · filed 2026-08-27
$1.20M
derived: sum of 2 quarters · filed 2026-08-27
$1.77M
derived: sum of 3 quarters · filed 2026-08-27
$2.34M
10-K · filed 2026-08-27
2026-03-31$572.00K
10-Q · filed 2026-05-06
$1.15M
derived: sum of 2 quarters · filed 2026-05-06
$1.72M
derived: sum of 3 quarters · filed 2026-05-06
2025-12-31$576.00K
10-Q · filed 2026-05-06
$1.15M
derived: sum of 2 quarters · filed 2026-05-06
2025-09-30$571.00K
10-Q · filed 2026-05-06
2025-06-30$2.07M
10-K · filed 2026-08-27
2025-03-31$503.00K
10-Q · filed 2026-05-06
$1.00M
derived: sum of 2 quarters · filed 2026-05-06
$1.50M
derived: sum of 3 quarters · filed 2026-05-06
2024-12-31$502.00K
10-Q · filed 2026-05-06
$1.00M
derived: sum of 2 quarters · filed 2026-05-06
2024-09-30$500.00K
10-Q · filed 2026-05-06
2024-06-30$6.94M
10-K · filed 2025-09-04
2024-03-31$448.00K
10-Q · filed 2025-05-06
$903.00K
derived: sum of 2 quarters · filed 2025-05-06
$6.44M
derived: sum of 3 quarters · filed 2025-05-06
2023-12-31$455.00K
10-Q · filed 2025-05-06
$5.99M
derived: sum of 2 quarters · filed 2025-05-06
2023-09-30$5.53M
10-Q · filed 2025-05-06
2023-06-30$1.59M
10-K · filed 2024-08-28
2023-03-31$383.00K
10-Q · filed 2023-05-04
$764.00K
derived: sum of 2 quarters · filed 2024-05-02
$1.14M
derived: sum of 3 quarters · filed 2024-05-02
2022-12-31$381.00K
10-Q · filed 2024-05-02
$758.00K
derived: sum of 2 quarters · filed 2024-05-02
2022-09-30$377.00K
10-Q · filed 2024-05-02
2022-06-30$378.00K
10-K · filed 2023-08-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41